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We appreciate the invitation from the editor of 
Seminars in Dialysis to express our opinions about 
a topic that is very acute in our personal and pro- 
fessional lives. In March 1993, Minntech Corpora- 
tion, which sells Renalina, filed a lawsuit in the 
United States District Court for the District of 
Maryland against the five authors of this editorial 
(plus one other person). Minntech is seeking over 
one million dollars in damages from us as individu- 
als based on our reports of scientific research find- 
ings. The suit claims damages to Minntech because 
our research had suggested an association of mortality 
nsks with the use of certain reuse agents, including 
Re&*, in conventional dialyzers in freestanding di- 
alysis units. Minntech subsequently publicized many 
of its allegations in letters to various journals (14).  
Until now, in our pursuit of scientific objectivity, 
we have abstained from publishing any written re- 
sponse to what we view as an unfounded legal suit. 
Our primary goal to date has been to publish the 
scientific results through the peer review process 
and to let the renal community judge the merit of 
this research. In fact, at the time of this writing the 
scientific research paper in question has been ac- 
cepted and is in press at the American Journal of 
Kidney Diseases (5) .  
Minntech’s decision to pursue litigation has been 
a subject of comment in this and other journals. A 
recent editorial by C. M. Kjellstrand in a previous 
issue of this journal (6) describes some of Minn- 
tech’s allegations. Other publications have ap- 
plauded the right for a legal challenge to scientific 
research (7) or have provided possible mechanisms 
and discussion explaining the associations that we 
reported (8-10). These publications follow other re- 
lated research (1 1-15). 
Although we are in agreement with much of Dr. 
Kjellstrand’s editorial, there are two assumptions in 
Dr. Kjellstrand’s editorial that require clarification 
and correction. Furthermore, we believe that the 
largely unilateral publicity and the assertions by 
Minntech should not go unanswered. 
Dr. KJellstrand Suggests that the Research May 
Have Been Presented Too Hastily 
Quite the contrary is the case. At the time of our 
discussions with representatives of several Federal 
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agencies, the research process regarding reuse ger- 
micides and patient outcomes had been underway 
for more than a year. The results of a pilot study 
had been reviewed by the Scientific Advisory Com- 
mittee of the USRDS in June and September of 
1592. The national study that was the focus of dis- 
cussions and review with federal health agencies 
(our present study) followed up this earlier re- 
search, and analytical work had been intensely pur- 
sued for at least five months. 
After discussing and reviewing our findings with 
federal health officials, we were directed by the 
Health Care Financing Administration (HCFA, the 
funding agency) to meet with representatives from 
HCFA, the Centers for Disease Control and Pre- 
vention (CDC) and the Food and Drug Administra- 
tion (FDA). To further discuss these results, we 
presented these findings to epidemiologists, statis- 
ticians, and other representatives of these agencies 
at several meetings in September 1992. Throughout 
this process, we were instructed by the sponsors of 
the research (HCFA) that the results were to be 
considered confidential. After these meetings, the 
FDA concluded that it was appropriate to schedule 
an invited session on October 8, 1992. At the FDA’s 
request, the authors presented their research find- 
ings at that meeting. The findings were also pre- 
sented to the dialysis community at the Annual 
Meeting of the American Society of Nephrology 
(ASN) in November 1592. In short, the study was 
thorough and precise, with careful and deliberate 
attention to detail. 
The authors communicated with Minntech repre- 
sentatives on numerous occasions in October and 
November 1992 and also met with several Minntech 
executives. During this period, the authors ex- 
plained their analytical methods and results to 
Minntech, provided statistical output to Minntech, 
and considered Minntech’s disagreements with the 
research. As part of a prepublication review pro- 
cess, a draft version of the study manuscript was 
sent in February 1993 for comment to federal of% 
cials who had been involved in the previous review 
process. A copy was also sent to Minntech and, as 
is normal in the scientific process, copies were also 
sent to a few knowledgeable researchers in the renal 
community for review. Minntech did not provide 
comments on the draft and instead proceeded with 
a lawsuit. 
In the course of studying and reporting data with 
potentially significant public health implications, 
we have proceeded in a careful, responsible, and 
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ethical manner. Suppressing, delaying, or otherwise 
withholding these findings from federal agencies or 
the dialysis community would have been wholly in- 
consistent with our obligations as researchers and 
with the interests of patients and dialysis providers. 
In our opinion, stopping or delaying publication of 
this paper and chilling open discussion of these find- 
ings have been major objectives of Minntech’s law- 
suit against the six authors. 
Dr. Kjellstrands Editorial Addressed Minntech’s 
Asserted Inability to Gain Access to the 
Underlying Data Used in our Analyses 
We agree with the principle that data upon which 
public health findings are based should be available 
for evaluation and assessment by the medical com- 
munity. At the same time, because much of these 
data involves medical information about identified 
patients, there is an obvious need for appropriate 
safeguards to protect the privacy of these patients. 
We have at all times willingly cooperated with both 
Minntech and federal health agencies in reconciling 
these interests. 
All researchers who work with patient data of the 
kind used in this research must, according to federal 
law (the Privacy Act, 5 U.S.C. Section 552 a [il 131, 
sign a confidentiality agreement not to release the 
data. The authors were therefore bound by federal 
law to keep the data confidential and not release 
them (Minntech was informed of this before it filed 
its lawsuit). Since the authors support the right of 
all researchers to carry out their own analysis of 
these data files, the authors met with representa- 
tives from Minntech and the Federal government in 
November 1992 to explain exactly how to go about 
gaining access to the data through submission of a 
research protocol. 
At Minntech’s request, the authors referred 
Minntech to a research firm that had had prior ac- 
cess to the federal data and could assist Minntech in 
obtaining and evaluating the data using the research 
protocol route that is open to all researchers. 
Minntech engaged this firm and notified its clients, 
the government, and the renal community that this 
firm, using the federal data, would be conducting its 
own analysis of the questions raised by our paper. 
Shortly thereafter, however, Minntech decided not 
to have this firm proceed with its plan to submit a 
research protocol, obtain the data, and conduct sta- 
tistical research. We do not h o w  the basis for 
Minntech’s decision. We have seen no evidence 
that Minntech notified its clients or the renal com- 
munity of its change in plans. 
Minntech instead chose to pursue litigation 
against the United States (in addition to its separate 
litigation against the authors), seeking the underly- 
ing medical data under the Freedom of Information 
Act. For present purposes, we need not speculate 
on the merits of that case or on Minntech’s motives 
for pursuing litigation rather than following the 
more conventional research process for obtaining 
access to these data. It is clear, however, that we 
have in no way concealed the data used in our anal- 
yses from Minntech, and any suggestion to that ef- 
fect is untrue. To the contrary, we made substantial 
efforts to help Minntech understand our research, 
gain access to the underlying data, and engage in 
independent analysis. 
Minntech Has Incorrectly implied That There Was 
a Conflict of Interest and the Research Was 
Biased Against Minntech 
Minntech has also attempted to discredit the re- 
search findings by attacking the messengers. 
Minntech’s implication that any of the six research- 
ers was biased or had a conflict of interest is not 
supported by the facts. (Notably, while Minntech 
was asserting this conflict of interest, Minntech it- 
self repeatedly relied on research findings and pre- 
sentations by Alan Collins, MD, often without any 
mention of the fact that Dr. Collins had been a paid 
consultant for Minntech.) 
The study initially presented at the FDA and 
ASN meetings was for patients treated in freestand- 
ing units which used predominantly conventional 
dialyzers. This subpopulation of the total U.S. di- 
alysis population was chosen before any analyses 
were done for two reasons: (i) since the database 
had limited information on comorbidities (age, race, 
gender, cause of renal failure), patients in freestand- 
ing units were chosen as a more stable and more 
homogeneous population than if patients treated in 
hospital units had been included; and (ii) since high- 
flux dialyzers are rarely used without reprocessing, 
we considered it difficult to find an adequate control 
group of units employing only single use. Thus our 
design was rational, consistent with previous re- 
search designs, and not driven by bias or selection 
of the most striking results. Subsequent analyses of 
other patient groups, including patients in hospital- 
based dialysis units and patients in units using high- 
flux dialyzers, are also reported in the final publi- 
cation (5). 
Regarding the authors and alleged conflicts of in- 
terest stemming from financial and other economic 
forces related to the issue of dialyzer reuse and 
Minntech, let us clearly state the facts. 
First, from the outset of this research, the authors 
never had a predisposition against dialy zer reuse. 
To the contrary, several of the authors had previ- 
ously published findings supportive of reuse ( 1 6  
17). (Notably, Mmtech has cited some of these 
pro-reuse findings in its product literature; appar- 
ently these favorable findings were not considered 
the product of bias). Indeed, after our research was 
presented to the government and the ASN, and 
prior to the filing of the lawsuit, Dr. Levin wrote an 
editorial in this journal that was supportive of reuse 
and urged that our findings be interpreted cau- 
tiously (18). Dr. Levin’s editorial cautioned (as we 
have in all presentations of these research findings) 
that the associations found in our analysis should 
not be interpreted as showing a causal relationship 
between Rendin@ reuse and mortality. 
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Second, our dialysis reuse research has been 
funded exclusively by agencies of the United States 
Government. No corporation or other private orga- 
nization had any involvement in the research, with 
the exception of our request for comments from 
Minntech and another company that currently sells 
a glutaraldehyde-based germicide.’ 
Finally, as to other activities of the authors, Drs. 
Held, Port, and Levin have spoken at professional 
meetings sponsored by manufacturers of dialysis 
products for which they received a speaker’s hon- 
orarium and travel expenses. In the case of Drs. 
Held and Port, the sponsor was the Baxter Health 
Care Corporation; for Dr. Levin the sponsor was 
Fresenius USA, Inc. Baxter has provided research 
support to the University of Michigan, Dr. Port’s 
professional base; Fresenius AG, a German corpo- 
ration, has provided research support to Beth Israel 
Medical Center, the professional base of Dr. Levin. 
Neither this research support nor the speaking en- 
gagements had anything to do with dialyzer reuse 
activities. In addition, Dr. Wolfe has consulted with 
National Medical Care, Inc., on issues undated to 
dialyzer reuse. Beth Israel Medical Center has been 
involved in the development of dialyzer heat steril- 
ization, a method for the reprocessing of dialyzers. 
This research has been conducted at no financial 
advantage to Dr. Levin. N o  research support has 
been paid to Dr. Levin or to Beth Israel Medical 
Center for dialyzer reprocessing research. Dr. 
Levin has not received consultant fees or any direct 
or indirect payment from Fresenius AG or Frese- 
nius USA, Inc. Dr, Levin owns less than YIO of 1% 
of the outstanding common stock of Fresenius 
USA, Inc., the shares of which are publicly traded. 
None of the authors have ever owned Minntech 
stock or had options to buy or sell Minntech stock. 
In reporting these facts, we go far beyond the 
disclosure that is required in even the most demand- 
ing research journals. (As noted above, we also go 
far beyond Minntech’s treatment of its direct finan- 
cial relationship with various physicians.) We do so 
because it is essential that our scientific findings be 
evaluated on their merits-not on the basis of un- 
founded rumor or personal attacks on the authors. 
The reality is that we were motivated to carry out 
and report this research solely by our interest in 
scientific research and in arriving at the correct sci- 
ence regarding the relative effectiveness of dflerent 
end-stage renal disease therapies. Even a strong 
b i a ~  could not have m&ed the epidemiologic and 
statistical analysis of over 60,OOO patient years of 
experience or the results of the study. The conclu- 
sions we reached from these data reflect our best 
professional judgment, and our analysis and conclu- 
sions have been extensively reviewed by profes- 
sional peers in the renal community as well as pro- 
fessional and governmental organizations. 
In presenting these findings in oral presentations 
and a forthcoming paper, we have been candid and 
forthright about the limitations of epidemiological 
studies, including this one. We repeatedly made 
considerable effort to emphasize that no causal link 
between use of a germicide and mortality risk could 
be inferred from these studies. We emphasized 
from the beginning that the variation in outcomes 
from unit to unit was large and that there were some 
dialysis units using all gemkides, including Rena- 
line, that had low mortaIity compared with the av- 
erage of units not reusing. 
In short, however much Minntech may dislike or 
disagree with our conclusions, we find its public 
effort to discredit these findings by attacking the 
authors to be without justification. It is irresponsi- 
ble and totally unfounded for Minntech to assert in 
a lawsuit and in letters to journals--as it has-that 
these researchers knowingly produced and dissem- 
inated false research. 
Germicide Efficacy Versus Effectiveness 
One of the points we have made repeatedly is that 
our associations cannot distinguish between the ef- 
fects of the germicide used in reprocessing and the 
manner in which the germicide is used. The latter 
might be called the “user factor.” Our research fo- 
cused on the “effectiveness” of reuse, which in- 
cludes both the “efficacy” of the product and the 
manner in which the product is used (user factor) in 
nonselected U.S. centers. 
Minntech has frequently made the claim that, if 
used as directed, RenalinQ is safe. Implicit in this 
claim is that Minntech is talking about “efficacy,” 
in contrast to our focus on “effectiveness,” which 
includes “efficacy” as well as the “user factor.” 
Indeed, we have fnquently pointed out that our 
results may not have been caused by the germicide 
itself, but instead may be explained by the manner 
in which it is used. Even if a n t e c h  is correct 
about the efficacy of R&u&n*, the statistical asso- 
ciations we have reported would still point to sub- 
stantial public health problems that may be present 
because of misuse of the product. Clearly the FDA 
policy response suspected a user problem since it 
focused on the methods of proper use of Redin@. 
One of the major reasons for presenting and pub- 
lishing the results of studies such as ours is to allow 
the scientific community to examine the evidence 
and consider what mechanisms might be responsi- 
ble for the observed association. To bring up an 
analogy, if use of an efficacious drug were associ- 
ated with an increase in mortality in a substantial 
subgroup of patients it would certainly call for in- 
tense scrutiny. Failure to report such a finding 
would be considered unethical. It was in this spirit 
that these results were discussed and reviewed by 
the authors with the HCFA, the CDC, the FDA, 
and the renal community. Should such reports be 
suppressed for fear of lawsuits? In this regard, Dr. 
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Kjellstrand’s editorial makes a very good point that 
the current litigation will only slow down the pro- 
cess of finding the truth in this matter. 
What Are the Lessons of this Experience 
for Research? 
We did not invite or welcome the litigation from 
Minntech. At the direction of federal sponsors and 
a scientific advisory committee, we diligently en- 
gaged in research addressing a significant public 
health issue and reported the findings accurately 
and responsibly to federal health agencies and the 
dialysis community. 
Minntech’s decision to resort to litigation in 
which it seeks more than one million dollars in al- 
leged damages from the investigators has diverted 
too much energy and money from research and has 
inserted fear of litigation into the scientific process. 
The defendants’ legal costs have been very substan- 
tial over the last year, even before entering the de- 
position phase. Trial is not likely until late 1994. 
One can only speculate what the ultimate expense 
of this litigation will be. We have been fortunate to 
have support from our institutions, which have not 
flinched at this challenge to the research process. 
What would have happened if we had not been so 
fortunate? What would happen to other researchers 
not as well supported by their institutions? And 
more importantly, what does the precedent of this 
lawsuit mean for the research process? At least one 
other research group has federal support to examine 
dialyzer reuse. Try to imagine the climate they face 
as they prepare to report their findings. Dr. Kjell- 
strand’s editorial provided a good summary of what 
this lawsuit means for the research process. 
There are at least two qualities of the legal system 
that are very detrimental to the research process. 
First, resolving legal disputes is costly and ex- 
tremely time-consuming; second, the legal system 
is not an efficient machine to find truth in complex 
scientific matters. 
The fact that our institutions have agreed to pay 
for legal fees so far does not make this litigation 
“free” to society. Just as the cost of medical mal- 
practice is passed on in higher prices to consumers 
and taxpayers, the cost of litigation in research will 
be passed on to others. This country does not need 
to have a substantial new cost burden in our current 
health care system. Just when our medical system is 
focusing on more studies of outcomes research such 
as our own project for the goal of a more efficient 
health care system, a new wrench is thrown into the 
works. Scientific issues will henceforth be threat- 
ened by the courts! 
What if errors are made in scientific research? As 
Dr. Kjellstrand noted, this will sometimes occur, 
but scientific processes exist to correct such errors. 
We suspect that this process is robust enough to 
deal with errors of many types, even those that 
could arise from conflicts of interest that are 
present in industry-sponsored research. 
One process is the manner in which studies are 
repeated and reproduced as part of scientific in- 
quiry. We believe that Minntech has the right to the 
federal data under the same conditions with which 
we and all researchers have had to  comply. 
Minntech should be able to confirm or challenge our 
results. There are established processes for re- 
searchers who want to gain access to the data, pro- 
cesses that assure appropriate confidentiality. In- 
stead of relying on a research proposal, however, 
Minntech has resorted to much more heavy-handed 
attacks, which pose different threats to society. Sci- 
entists differ with each other often. To challenge 
published research, a scientist typically builds an- 
other experiment with other data, other methods, 
andor other theoretical models. Over time, the er- 
rors of the past are bypassed, refuted, and replaced 
by more complete and accurate results. 
Our advice to Minntech before the litigation was 
to take the high road. This approach might have 
included making a public statement saying i t  
thought these six researchers were wrong and that 
Minntech was going to show them to be wrong. We 
further advised them that if their investigation 
found that there is something to these associations 
and that the problem lies with Minntech products or 
how they are used, Minntech as a reputable and 
respected company should have fixed matters. That 
advice still stands, but we now believe that 
Minntech should also repair some of the damage it 
has done to the scientific research process by reim- 
bursing the Urban Institute, the University of Mich- 
igan, and Beth Israel Hospital for legal expenses. 
The current message Minntech has given to the re- 
search community is that those who report adverse 
facts about experience with Minntech products may 
suffer legal expenses from litigation and unfounded 
accusations in the literature. Failure to reverse 
these actions and reimburse the expenses already 
incurred would stand as a signal to those who might 
naively believe that they could comment on their 
experience with Renalinm in a free exchange of 
facts. 
Our scientific advice to Minntech at the initial 
presentations was to test whether the reuse proce- 
dures with Renalina differed between units with 
high and low standardized mortality rates. We pro- 
posed that we identify dialysis units using RenalinB 
with the highest and lowest standardized mortality 
rates and blind Minntech to their grouping. On-site 
data collection and analysis had a very high proba- 
bility of determining whether the “user factors” 
may be an explanation for the observed differences 
in mortality. It was our belief that this study could 
have been completed in early 1993. To our knowl- 
edge, this advice was not followed and the study 
was never implemented. 
The data we used were for 198!3-1990. We hope 
that if the “user factor” was the cause of the ele- 
vated mortality that our study might have already 
led to improvements in practices. It appears that the 
FDA notice had that intent. 
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To those readers who have heard so much rumor 
and innuendo about the authors that they suspect 
that the authors must have done something to de- 
serve such litigation we offer the following analogy: 
“Henry, why are you here?” Ralph Waldo Emer- 
son is supposed to have asked Thoreau, who was in 
jail for refusing to pay war taxes. “Waldo, why are 
you not here?” Thoreau replied. 
The current litigation from Minntech must not 
and will not deter us and others from continuing to 
researcb dialysis-related issues and report scientific 
findings with potential public health implications. 
We do invite and welcome scientific questions and 
challenges. We clearly see a need for continued, 
quality research in this area to identify the reasons 
for the observed differences in mortality. Research 
findings are rarely an endpoint. Our studies provide 
new findings and answer some questions while rais- 
ing new questions which need to be addressed in 
future research for the pursuit of truth. We hope 
that the medical community wili demonstrate their 
defense of the scientific process through condem- 
nation of inappropriate litigation. We hope that 
Minntech will take tangible action to repair the 
damage that their litigation has done to the scientific 
process and to show their commitment to preserv- 
ing scientific inquiry. 
Note Added in Proof 
On February 15, 1994, very close to the time of 
writing of this editorial, Minntech filed a research 
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